Dyskinesia (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dyskinesia" in English language version.

refsWebsite

Global rank English rank

16nih.gov

4^th place

12doi.org

2^nd place

2books.google.com

3^rd place

1yahoo.net

7,590^th place

4,698^th place

1web.archive.org

1^st place

1drugandalcoholdependence.com

low place

1semanticscholar.org

11^th place

8^th place

1lu.se

4,012^th place

4,295^th place

books.google.com

Healy 2008, p. 29-30. Healy, David (2008). Psychiatric Drugs Explained. Elsevier Health Sciences. ISBN 978-0-7020-2997-4.
Healy 2008, p. 30–31. Healy, David (2008). Psychiatric Drugs Explained. Elsevier Health Sciences. ISBN 978-0-7020-2997-4.

doi.org

Rusinyak, Daniel E. (2011). "Neurologic manifestations of chronic methamphetamine abuse". Neurologic Clinics. 29 (3): 641–655. doi:10.1016/j.ncl.2011.05.004. PMC 3148451. PMID 21803215.
Hanson, Glen R.; Fleckenstein, Annette E.; Curtin, Kare (1 January 2015). "Dependence on amphetamines increases Parkinson's disease: Effect of gender". Drug and Alcohol Dependence. 146: e134 – e135. doi:10.1016/j.drugalcdep.2014.09.284. Retrieved 28 November 2017.
Kish, Stephen J.; Boileau, Isabelle; Callaghan, Russell C.; Tong, Junchao (2017). "Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease – a critical assessment of the evidence". European Journal of Neuroscience. 45 (1): 58–66. doi:10.1111/ejn.13363. PMC 5209286. PMID 27519465.
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (April 2007). "Levodopa-induced dyskinesias". Movement Disorders. 22 (10): 1379–89. doi:10.1002/mds.21475. PMID 17427940. S2CID 20926751.
Thanvi B, Lo N, Robinson T (June 2007). "Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment". Postgraduate Medical Journal. 83 (980): 384–88. doi:10.1136/pgmj.2006.054759. PMC 2600052. PMID 17551069. (full free text)
Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P (November 2012). "Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations". Journal of Neuroscience. 32 (47): 16541–51. doi:10.1523/JNEUROSCI.3047-12.2012. PMC 6621755. PMID 23175810. (full free text)
Gonzales GR (July 1992). "Postherpes simplex type 1 neuralgia simulating postherpetic neuralgia". J Pain Symptom Manage. 7 (5): 320–3. doi:10.1016/0885-3924(92)90065-p. PMID 1624816.
Pranzatelli MR (September 1996). "Antidyskinetic drug therapy for pediatric movement disorders". J Child Neurol. 11 (5): 355–369. doi:10.1177/088307389601100503. PMID 8877602.
Chase TN, Oh JD, Konitsiotis S (April 2000). "Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms". J Neurol. 247 Suppl 2: II36 – II42. doi:10.1007/pl00007759. PMID 10991664.
Rylander D (January 2012). "The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery". Parkinsonism Relat Disord. 18 Suppl 1: S126 – S128. doi:10.1016/S1353-8020(11)70039-6. PMID 22166409.
Kwon DK, Kwatra M, Wang J, Ko HS (November 2022). "Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies". Cells. 11 (23): 3736. doi:10.3390/cells11233736. PMC 9736114. PMID 36496996.
Bashir HH, Jankovic J (May 2020). "Treatment of Tardive Dyskinesia". Neurol Clin. 38 (2): 379–396. doi:10.1016/j.ncl.2020.01.004. PMID 32279716.

drugandalcoholdependence.com

Hanson, Glen R.; Fleckenstein, Annette E.; Curtin, Kare (1 January 2015). "Dependence on amphetamines increases Parkinson's disease: Effect of gender". Drug and Alcohol Dependence. 146: e134 – e135. doi:10.1016/j.drugalcdep.2014.09.284. Retrieved 28 November 2017.

lu.se

lup.lub.lu.se

Rylander D (January 2012). "The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery". Parkinsonism Relat Disord. 18 Suppl 1: S126 – S128. doi:10.1016/S1353-8020(11)70039-6. PMID 22166409.

nih.gov

pubmed.ncbi.nlm.nih.gov

Rusinyak, Daniel E. (2011). "Neurologic manifestations of chronic methamphetamine abuse". Neurologic Clinics. 29 (3): 641–655. doi:10.1016/j.ncl.2011.05.004. PMC 3148451. PMID 21803215.
Kish, Stephen J.; Boileau, Isabelle; Callaghan, Russell C.; Tong, Junchao (2017). "Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease – a critical assessment of the evidence". European Journal of Neuroscience. 45 (1): 58–66. doi:10.1111/ejn.13363. PMC 5209286. PMID 27519465.
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (April 2007). "Levodopa-induced dyskinesias". Movement Disorders. 22 (10): 1379–89. doi:10.1002/mds.21475. PMID 17427940. S2CID 20926751.
Thanvi B, Lo N, Robinson T (June 2007). "Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment". Postgraduate Medical Journal. 83 (980): 384–88. doi:10.1136/pgmj.2006.054759. PMC 2600052. PMID 17551069. (full free text)
Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P (November 2012). "Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations". Journal of Neuroscience. 32 (47): 16541–51. doi:10.1523/JNEUROSCI.3047-12.2012. PMC 6621755. PMID 23175810. (full free text)
Gonzales GR (July 1992). "Postherpes simplex type 1 neuralgia simulating postherpetic neuralgia". J Pain Symptom Manage. 7 (5): 320–3. doi:10.1016/0885-3924(92)90065-p. PMID 1624816.
Pranzatelli MR (September 1996). "Antidyskinetic drug therapy for pediatric movement disorders". J Child Neurol. 11 (5): 355–369. doi:10.1177/088307389601100503. PMID 8877602.
Chase TN, Oh JD, Konitsiotis S (April 2000). "Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms". J Neurol. 247 Suppl 2: II36 – II42. doi:10.1007/pl00007759. PMID 10991664.
Rylander D (January 2012). "The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery". Parkinsonism Relat Disord. 18 Suppl 1: S126 – S128. doi:10.1016/S1353-8020(11)70039-6. PMID 22166409.
Kwon DK, Kwatra M, Wang J, Ko HS (November 2022). "Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies". Cells. 11 (23): 3736. doi:10.3390/cells11233736. PMC 9736114. PMID 36496996.
Bashir HH, Jankovic J (May 2020). "Treatment of Tardive Dyskinesia". Neurol Clin. 38 (2): 379–396. doi:10.1016/j.ncl.2020.01.004. PMID 32279716.

ncbi.nlm.nih.gov

Rusinyak, Daniel E. (2011). "Neurologic manifestations of chronic methamphetamine abuse". Neurologic Clinics. 29 (3): 641–655. doi:10.1016/j.ncl.2011.05.004. PMC 3148451. PMID 21803215.
Kish, Stephen J.; Boileau, Isabelle; Callaghan, Russell C.; Tong, Junchao (2017). "Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease – a critical assessment of the evidence". European Journal of Neuroscience. 45 (1): 58–66. doi:10.1111/ejn.13363. PMC 5209286. PMID 27519465.
Thanvi B, Lo N, Robinson T (June 2007). "Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment". Postgraduate Medical Journal. 83 (980): 384–88. doi:10.1136/pgmj.2006.054759. PMC 2600052. PMID 17551069. (full free text)
Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P (November 2012). "Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations". Journal of Neuroscience. 32 (47): 16541–51. doi:10.1523/JNEUROSCI.3047-12.2012. PMC 6621755. PMID 23175810. (full free text)
Kwon DK, Kwatra M, Wang J, Ko HS (November 2022). "Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies". Cells. 11 (23): 3736. doi:10.3390/cells11233736. PMC 9736114. PMID 36496996.

semanticscholar.org

api.semanticscholar.org

Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (April 2007). "Levodopa-induced dyskinesias". Movement Disorders. 22 (10): 1379–89. doi:10.1002/mds.21475. PMID 17427940. S2CID 20926751.